Medications for Psoriasis
For mild psoriasis, prescribe topical corticosteroids (ultrahigh potency/class 1) combined with vitamin D analogues (calcipotriene/calcipotriol) as first-line therapy, while for moderate to severe psoriasis, biologics targeting IL-17 (ixekizumab, secukinumab, bimekizumab), IL-23 p19 (risankizumab, guselkumab), or infliximab should be considered first-line options based on their superior efficacy. 1, 2, 3
Topical Therapies (Mild Psoriasis)
First-Line Topical Options
- Combination therapy is superior to monotherapy: Calcipotriene 0.005% plus betamethasone dipropionate 0.064% once or twice daily achieves 69-74% clear/almost clear status at 52 weeks versus 27% with vehicle 1
- Class 1 ultrahigh potency topical corticosteroids are recommended with strength of recommendation A 1
- Vitamin D analogues (calcipotriene, calcitriol, tacalcitol, maxacalcitol) for up to 52 weeks are recommended (strength A) 1
- Calcipotriene foam or calcipotriene/betamethasone gel for scalp psoriasis (4-12 weeks, strength A) 1
- Tacalcitol or calcipotriene with hydrocortisone for facial psoriasis (8 weeks, strength B) 1
Practical Topical Regimens
- Weekday/weekend approach: Vitamin D analogues twice daily on weekdays + high-potency corticosteroids twice daily on weekends for maintenance (strength B) 1
- Morning/evening split: High-potency corticosteroids in morning + vitamin D analogues in evening (strength B) 1
Critical Topical Pitfalls
- Avoid salicylic acid with calcipotriene - the acidic pH inactivates calcipotriene 1
- Apply vitamin D analogues AFTER phototherapy - UVA decreases calcipotriene concentration; thick calcipotriene layers block UVB 1
Systemic Therapies (Moderate to Severe Psoriasis)
Biologics (First-Line for Moderate-Severe Disease)
The most effective biologics are infliximab, bimekizumab, ixekizumab, and risankizumab, with similar clinical effectiveness when compared head-to-head 2. The AAD-NPF guidelines recommend biologics as first-line treatment for moderate to severe plaque psoriasis due to superior efficacy and acceptable safety profiles 3.
IL-17 Inhibitors
IL-23 p19 Inhibitors
- Risankizumab, guselkumab, tildrakizumab, mirikizumab 3
- Risankizumab and guselkumab now also approved for inflammatory bowel disease (Crohn's disease, ulcerative colitis) - making them preferred choices when IBD comorbidity exists 4
IL-12/23 p40 Inhibitor
- Ustekinumab 3
TNF-α Inhibitors
Oral Small Molecules
Phosphodiesterase 4 Inhibitor
JAK Inhibitor (Off-Label)
- Tofacitinib 5 mg twice daily or 10 mg twice daily (higher efficacy but increased adverse effects) 6
- NOT FDA-approved for psoriasis but can be considered 6
- Requires Shingrix vaccination before initiation 6
- Do not initiate if: Lymphocytes <500/mm³, ANC <1000/mm³, hemoglobin <9 g/dL 6
- Avoid with potent immunosuppressants (azathioprine, cyclosporine) or other biologics 6
- Dose reduction to 5 mg once daily with moderate/severe renal or hepatic impairment 6
Traditional Oral Systemic Agents
Methotrexate
- Traditional first-line oral agent 3
- Can be combined with topical calcipotriene (strength A recommendation) 1
Acitretin (Vitamin A Derivative)
- Most commonly prescribed for erythrodermic psoriasis (42.5%) and generalized pustular psoriasis (42.2%) in Japan 5
- Can be combined with topical calcipotriene 1
- CRITICAL CONTRAINDICATION: Women cannot consider pregnancy for 3 YEARS after discontinuation 6
- Forms etretinate with concurrent alcohol ingestion 6
- NOT a teratogen for male patients 6
- Requires monthly LFTs and lipid profiles for first 3 months, then every 3 months 6
Cyclosporine
- Can be combined with calcipotriene/betamethasone at low dose (2 mg/kg/day) for moderate-severe psoriasis (strength B) 1
Combination Strategies
Topicals + Biologics
- Class 1 corticosteroid + etanercept for 12 weeks (strength A) 1
- Calcipotriene/betamethasone + adalimumab for 16 weeks to accelerate clearance (strength B) 1
- All topical corticosteroids can be combined with any biologic (strength C) 1
Phototherapy
- Narrowband UV-B is the most commonly prescribed light therapy 3
Special Populations
Elderly Patients
Real-world data shows elderly patients more commonly receive phosphodiesterase 4 inhibitors or vitamin A derivatives as index treatment compared to younger patients 5
Psoriatic Arthritis
Biologics are more commonly selected for patients with psoriatic arthritis; specifically TNF-α inhibitors, IL-17 inhibitors, and p40IL-12/23 inhibitors are approved for this indication 5, 3
Latent Tuberculosis
The updated German guidelines extensively revised recommendations for interferon-gamma release assays, chest radiography indications, and suitability of systemic therapies in latent TB 4
Treatment Duration and Patterns
Real-world data demonstrates that over approximately 30 months, >85% of patients receive three or fewer lines of systemic therapy, and approximately 50% remain on at least one systemic drug throughout treatment 5. Biologics generally show longer time to discontinuation than oral medications 5.